A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy

Clear-cell Metastatic Renal Cell Carcinoma Clinical Trial

— A-PREDICT  

Official title:

A-PREDICT: A Phase II Study Of Axitinib In Metastatic Renal Cell Cancer in Patients Unsuitable for Nephrectomy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01693822
• Other study ID #: ICR-CTSU/2011/10033
• Status: Completed
• Phase: Phase 2
• Start date: October 2012
• Est. completion date: February 28, 2022

Study information

• Verified date: January 2024
• Source: Institute of Cancer Research, United Kingdom
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A-PREDICT is a study of axitinib in patients with metastatic renal cell carcinoma unsuitable for nephrectomy (as judged by the treating clinician) to evaluate efficacy, safety, toxicity and changes in biomarkers during therapy. Axitinib will given twice daily by mouth according to tolerability of treatment, for as long as patients are deriving clinical benefit. Blood and tumour tissue samples will be taken prior to and during therapy to evaluate biomarkers of treatment response. The primary clinical objective of this study is to define the activity of axitinib given to patients with metastatic renal cell carcinoma unsuitable for nephrectomy.

Description:

A-PREDICT is a single arm, single agent, open label, multicentre, phase II study of axitinib in patients with metastatic renal cell carcinoma of predominant clear cell histology and unsuitable for debulking nephrectomy (as judged by the treating clinician). Patients who have provided consent and have satisfied the eligibility criteria will be registered into the trial. The starting dose of axitinib will be 5 mg twice daily by mouth, escalating to a maximum of 10mg twice daily by mouth according to tolerability of treatment, for as long as patients are deriving clinical benefit. Treatment will be paused for one week prior to percutaneous biopsy of the primary on day 1 week 9. Disease progression will be evaluated according to RECIST v1.1 criteria 8 weeks after commencing treatment, at 8 weekly intervals to 6 months and 3 monthly thereafter. Blood and tumour tissue samples will be taken prior to and during therapy to evaluate biomarkers of treatment response. Nephrectomy will be carried out on any patient who becomes suitable in the opinion of the treating clinician during the course of the trial. Where possible, tissue samples will be taken from resected specimens. Response to axitinib in marker lesions will be correlated with changes in biomarkers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: February 28, 2022
• Est. primary completion date: March 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed metastatic renal cell carcinoma of predominant clear cell histology

2. Unsuitable for nephrectomy

3. Unsuitable for 'watch and wait' policy

4. No prior systemic therapy for renal cell carcinoma

5. Measurable metastatic disease using RECIST v1.1

6. Life expectancy 12 weeks or greater

7. ECOG performance status 0 or 1

8. Adequate organ function as defined by serum aspartate transaminase (AST) or serum alanine transaminase (ALT) =2.5 x upper limit of normal (ULN), or AST and ALT =5 x ULN if liver function abnormalities are due to liver metastases; total serum bilirubin =1.5 x ULN

9. Adequate haematological function as defined by absolute neutrophil count (ANC) =1500/µL, platelets =75,000/µL, haemoglobin =9.0 g/dL and prothrombin time (PT) =1.5 x ULN

10. Serum creatinine =1.5 x ULN or calculated creatinine clearance = 60 mL/min;

11. Urinary protein <2+ by urine dipstick.

12. No evidence of pre-existing uncontrolled hypertension

13. Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment.

14. Willingness and ability to comply with study procedures, including tumour biopsies.

15. Written informed consent

Exclusion Criteria:

1. The presence of intracranial disease, unless stable >6 months. In the case of a solitary brain metastasis which has been resected, there must be evidence of a disease-free interval of at least 3 months post-surgery. All patients previously treated for brain metastases must be stable off corticosteroid therapy for at least 28 days.

2. The presence of active second malignancy.

3. Women who are pregnant or are breastfeeding. Female patients must be surgically sterile, be postmenopausal, or must agree to use effective contraception during the period of therapy.

4. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy.

5. Current signs or symptoms of severe progressive or uncontrolled hepatic, endocrine, pulmonary disease other than directly related to RCC.

6. Gastrointestinal abnormalities including:

1. inability to take oral medication;

2. requirement for intravenous alimentation;

3. prior surgical procedures affecting absorption including total gastric resection;

4. treatment for active peptic ulcer disease in the past 6 months;

5. active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy;

6. malabsorption syndromes.

7. Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors (see section 8.12, concomitant therapy).

8. Current use or anticipated need for treatment with drugs that are known CYP3A4 or CYP1A2 inducers (see section 8.12, concomitant therapy).

9. Requirement of anticoagulant therapy with oral vitamin K antagonists. Low-dose anticoagulants for maintenance of patency of central venous access device or prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular weight heparin is allowed.

10. Active seizure disorder, spinal cord compression, or carcinomatous meningitis.

11. Any of the following within 12 months prior to study entry: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack.

12. Deep vein thrombosis or pulmonary embolism within 6 months prior to study entry.

13. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.

14. Known galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Clear-cell Metastatic Renal Cell Carcinoma

Intervention

Drug:
• Axitinib
Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities. Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy. Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day. Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol.

Locations

Country	Name	City	State
United Kingdom	Addenbrooke's Hospital	Cambridge
United Kingdom	Western General Hospital	Edinburgh
United Kingdom	Royal Surrey County Hospital	Guildford	Surrey
United Kingdom	Leeds Teaching Hospitals NHS Trust	Leeds
United Kingdom	Guy's Hospital	London
United Kingdom	Royal Free Hospital	London
United Kingdom	Royal Marsden Hospital	London
United Kingdom	Royal Marsden Hospital - Sutton	London	Sutton
United Kingdom	Christie Hospital	Manchester
United Kingdom	Derriford Hospital	Plymouth
United Kingdom	The Clatterbridge Cancer Centre NHS Foundation Trust	Wirral

Sponsors (3)

Lead Sponsor	Collaborator
Institute of Cancer Research, United Kingdom	Pfizer, Royal Marsden NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	EXPLORATORY ENDPOINT: Molecular and pathological changes in biomarkers as a consequence of axitinib therapy		Treatment duration (Baseline, Day 1 week 8, and again at disease progression)
Primary	Freedom from progression at 6 months	The proportion of study participants alive and progression free at 6 months (day 1 week 25 visit). Progression will be measured from the date of study entry (registration date) until the first date of either death or confirmed progressive disease according to RECIST. Patients alive and free from progression will be censored at the date of last follow-up. The proportion of patients progression free at 6 months will be reported with 95% confidence interval. In addition, progression free survival will be presented using the Kaplan Meier product limit method with median progression free survival reported. A blinded central review of CT scans will be conducted for verification purposes.	6 months
Secondary	Best overall response	Best tumour response that is achieved during or within 30 days after termination of axitinib that is confirmed according to RECIST	During treatment +30 days
Secondary	Progression free survival	Progression-free survival (PFS) will be measured from the date of registration until first date of either death or confirmed progressive disease according to RECIST 1.1. Time to last follow-up will be used if patient has not progressed or died and PFS time for the patient will be considered censored. A Kaplan Meier graph and median survival time will be presented.	Study duration (assessed week 9, 17, 25, and 4 weekly until progression)
Secondary	Overall survival	Overall survival will be measured from the date of registration until the date of death due to any cause. Time to last follow-up will be used if patient has not died and survival time for the patient will be considered censored.	Study duration (estimated median overall survival (OS) of 10.9 months)
Secondary	Safety and toxicity of axitinib (by NCI CTC grading version 4)		Treatment duration (at least 4 weekly, and again at disease progression - likely to be 6 months)
Secondary	Number of patients who become suitable for nephrectomy as a consequence of therapy with axitinib	The proportion of patients who undergo nephrectomy following registration as a result of treatment with axitinib will be reported with 95% confidence intervals.	Study duration (assessed by clinician over treatment duration which is estimated at 6 months)